18th Jul 2016 06:41
LONDON (Alliance News) - Pharmaceutical company GlaxoSmithKline PLC on Monday said China's Food & Drug Administration has approved its Cervarix vaccine for the prevention of cervical cancer.
The treatment is the first vaccine against human papilloma virus to have been approved in China and a commercial launch of the drug is anticipated in early 2017.
Glaxo said the drug was tested over the course of six years in China and has been registered for use in the country on girls and women between 9 and 25 years old.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline